Clever Leaves Holdings Inc. (CLVR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.02 Million USD | -39.9% |
| 2022 | 11.69 Million USD | -73.06% |
| 2021 | 43.39 Million USD | -15.86% |
| 2020 | 51.56 Million USD | 13.27% |
| 2019 | 45.52 Million USD | 74.22% |
| 2018 | 26.13 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 9.46 Million USD | -19.02% |
| 2023 FY | 7.02 Million USD | -39.9% |
| 2023 Q2 | 8.88 Million USD | -6.16% |
| 2023 Q3 | 8.08 Million USD | -8.95% |
| 2023 Q4 | 7.02 Million USD | -13.13% |
| 2022 FY | 11.69 Million USD | -73.06% |
| 2022 Q4 | 11.69 Million USD | -1.88% |
| 2022 Q3 | 11.91 Million USD | -42.92% |
| 2022 Q2 | 20.87 Million USD | -53.38% |
| 2022 Q1 | 44.76 Million USD | 3.18% |
| 2021 Q2 | 70.95 Million USD | -4.43% |
| 2021 Q1 | 74.24 Million USD | 43.97% |
| 2021 FY | 43.39 Million USD | -15.86% |
| 2021 Q4 | 43.39 Million USD | -18.84% |
| 2021 Q3 | 53.46 Million USD | -24.64% |
| 2020 Q4 | 51.56 Million USD | -4.47% |
| 2020 FY | 51.56 Million USD | 13.27% |
| 2020 Q3 | 53.98 Million USD | 9.35% |
| 2020 Q2 | 49.36 Million USD | -21.82% |
| 2020 Q1 | 63.14 Million USD | 38.7% |
| 2019 Q4 | 45.52 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | 45.52 Million USD | 74.22% |
| 2018 FY | 26.13 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 94.867% |
| PainReform Ltd. | 2.69 Million USD | -161.093% |
| Alvotech | 1.88 Billion USD | 99.627% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.259% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.51% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 95.713% |
| Journey Medical Corporation | 56.49 Million USD | 87.564% |
| Dynavax Technologies Corporation | 375.02 Million USD | 98.127% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.937% |
| Bright Green Corporation | 6.43 Million USD | -9.132% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 99.002% |
| Embecta Corp. | 2.03 Billion USD | 99.655% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14.437% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14.437% |
| SCYNEXIS, Inc. | 55.45 Million USD | 87.329% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 67.038% |
| Silver Spike Investment Corp. | 3 Million USD | -133.435% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 23.602% |
| Alpha Teknova, Inc. | 38.55 Million USD | 81.775% |
| Safety Shot Inc | 3.89 Million USD | -80.522% |
| Procaps Group, S.A. | 462.06 Million USD | 98.479% |
| Cosmos Health Inc. | 30.25 Million USD | 76.775% |
| Theratechnologies Inc. | 98.63 Million USD | 92.877% |
| Harrow Health, Inc. | 241.75 Million USD | 97.094% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 19.758% |
| Biofrontera Inc. | 23.13 Million USD | 69.636% |
| DURECT Corporation | 30.4 Million USD | 76.893% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.559% |
| Cronos Group Inc. | 43.73 Million USD | 83.935% |
| OptiNose, Inc. | 194.33 Million USD | 96.385% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.14% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 85.497% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 66.508% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 96.126% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -86.261% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 86.621% |
| Radius Health, Inc. | 804.29 Million USD | 99.126% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 48.918% |
| ProPhase Labs, Inc. | 42.54 Million USD | 83.485% |
| Phibro Animal Health Corporation | 725.54 Million USD | 99.032% |
| Procaps Group S.A. | 462.06 Million USD | 98.479% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 49.893% |
| Viatris Inc. | 27.21 Billion USD | 99.974% |
| Rockwell Medical, Inc. | 30.88 Million USD | 77.249% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 92.226% |
| SIGA Technologies, Inc. | 57.97 Million USD | 87.881% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.212% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 96.803% |
| Shineco, Inc. | 47.6 Million USD | 85.24% |
| PetIQ, Inc. | 645.22 Million USD | 98.911% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -3100.736% |
| Incannex Healthcare Limited | 5.83 Million USD | -20.515% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.311% |
| Alimera Sciences, Inc. | 107.35 Million USD | 93.455% |
| Assertio Holdings, Inc. | 148.41 Million USD | 95.266% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -270.576% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 17.249% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 95.948% |
| Hempacco Co., Inc. | 18.82 Million USD | 62.672% |
| Talphera, Inc. | 6.29 Million USD | -11.701% |
| Alvotech | 1.88 Billion USD | 99.627% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 95.929% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 99.159% |
| Currenc Group, Inc. | 177.67 Million USD | 96.046% |
| Kamada Ltd. | 109.96 Million USD | 93.611% |
| Indivior PLC | 1.95 Billion USD | 99.64% |
| Evoke Pharma, Inc. | 9.64 Million USD | 27.177% |
| Flora Growth Corp. | 17.22 Million USD | 59.203% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 17.249% |
| Evolus, Inc. | 209.68 Million USD | 96.649% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.69% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.196% |
| Akanda Corp. | 12.66 Million USD | 44.541% |